Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes.

Meroni M, Dongiovanni P, Longo M, Carli F, Baselli G, Rametta R, Pelusi S, Badiali S, Maggioni M, Gaggini M, Fracanzani AL, Romeo S, Gatti S, Davidson NO, Gastaldelli A, Valenti L.

EBioMedicine. 2020 Feb 11;52:102658. doi: 10.1016/j.ebiom.2020.102658. [Epub ahead of print]

2.

Dysmetabolic hyperferritinemia and dysmetabolic iron overload syndrome (DIOS): two related conditions or different entities?

Rametta R, Fracanzani AL, Fargion S, Dongiovanni P.

Curr Pharm Des. 2020 Jan 30. doi: 10.2174/1381612826666200131103018. [Epub ahead of print]

PMID:
32003680
3.

Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker.

Baselli GA, Dongiovanni P, Rametta R, Meroni M, Pelusi S, Maggioni M, Badiali S, Pingitore P, Maurotti S, Montalcini T, Taliento AE, Prati D, Rossi G, Fracanzani AL, Mancina RM, Romeo S, Valenti L.

Gut. 2020 Jan 30. pii: gutjnl-2019-319226. doi: 10.1136/gutjnl-2019-319226. [Epub ahead of print]

4.

Non-alcoholic fatty liver disease and cardiovascular disease: A still debated liaison.

Dongiovanni P, Ruscica M.

Eur J Prev Cardiol. 2019 Dec 18:2047487319895402. doi: 10.1177/2047487319895402. [Epub ahead of print] No abstract available.

PMID:
31852301
5.

Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis.

Cai B, Dongiovanni P, Corey KE, Wang X, Shmarakov IO, Zheng Z, Kasikara C, Davra V, Meroni M, Chung RT, Rothlin CV, Schwabe RF, Blaner WS, Birge RB, Valenti L, Tabas I.

Cell Metab. 2020 Feb 4;31(2):406-421.e7. doi: 10.1016/j.cmet.2019.11.013. Epub 2019 Dec 12.

PMID:
31839486
6.

Impact of natural neuromedin-B receptor variants on iron metabolism.

Rametta R, Dongiovanni P, Baselli GA, Pelusi S, Meroni M, Fracanzani AL, Busti F, Castagna A, Scarlini S, Corradini E, Pietrangelo A, Girelli D, Fargion S, Valenti L.

Am J Hematol. 2020 Feb;95(2):167-177. doi: 10.1002/ajh.25679. Epub 2019 Dec 16.

PMID:
31724192
7.

The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.

Meroni M, Longo M, Dongiovanni P.

Nutrients. 2019 Nov 4;11(11). pii: E2642. doi: 10.3390/nu11112642. Review.

8.

mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance.

Meroni M, Longo M, Erconi V, Valenti L, Gatti S, Fracanzani AL, Dongiovanni P.

Nutrients. 2019 Oct 29;11(11). pii: E2597. doi: 10.3390/nu11112597.

9.

β-Klotho gene variation is associated with liver damage in children with NAFLD.

Dongiovanni P, Crudele A, Panera N, Romito I, Meroni M, De Stefanis C, Palma A, Comparcola D, Fracanzani AL, Miele L, Valenti L, Nobili V, Alisi A.

J Hepatol. 2019 Oct 23. pii: S0168-8278(19)30613-0. doi: 10.1016/j.jhep.2019.10.011. [Epub ahead of print]

10.

Alcohol or Gut Microbiota: Who Is the Guilty?

Meroni M, Longo M, Dongiovanni P.

Int J Mol Sci. 2019 Sep 14;20(18). pii: E4568. doi: 10.3390/ijms20184568. Review.

11.

Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures.

Gomaraschi M, Fracanzani AL, Dongiovanni P, Pavanello C, Giorgio E, Da Dalt L, Norata GD, Calabresi L, Consonni D, Lombardi R, Branchi A, Fargion S.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Dec;1864(12):158523. doi: 10.1016/j.bbalip.2019.158523. Epub 2019 Sep 7.

PMID:
31505261
12.

The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.

Prill S, Caddeo A, Baselli G, Jamialahmadi O, Dongiovanni P, Rametta R, Kanebratt KP, Pujia A, Pingitore P, Mancina RM, Lindén D, Whatling C, Janefeldt A, Kozyra M, Ingelman-Sundberg M, Valenti L, Andersson TB, Romeo S.

Sci Rep. 2019 Aug 12;9(1):11585. doi: 10.1038/s41598-019-47737-w.

13.

Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.

Di Mauro S, Scamporrino A, Petta S, Urbano F, Filippello A, Ragusa M, Di Martino MT, Scionti F, Grimaudo S, Pipitone RM, Privitera G, Di Pino A, Scicali R, Valenti L, Dongiovanni P, Fracanzani A, Rabuazzo AM, Craxì A, Purrello M, Purrello F, Piro S.

Liver Int. 2019 Sep;39(9):1742-1754. doi: 10.1111/liv.14167. Epub 2019 Jun 26.

14.

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients.

Dongiovanni P, Meroni M, Baselli G, Mancina RM, Ruscica M, Longo M, Rametta R, Cespiati A, Pelusi S, Ferri N, Ranzani V, Nobili V, Pihlajamaki J, Fracanzani AL, Badiali S, Petta S, Fargion S, Romeo S, Kozlitina J, Valenti L.

J Lipid Res. 2019 Jun;60(6):1144-1153. doi: 10.1194/jlr.P090449. Epub 2019 Mar 27.

PMID:
30918065
15.

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.

Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, Aghemo A, D'Ambrosio R, Xing C, Romeo S, De Francesco R, Reeves HL, Valenti LVC.

Sci Rep. 2019 Mar 6;9(1):3682. doi: 10.1038/s41598-019-39998-2.

16.

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.

Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, Maggioni M, Craxi A, Fargion S, Prati D, Nobili V, Bugianesi E, Romeo S, Pihlajamaki J, Petta S, Valenti L.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2310-2319.e6. doi: 10.1016/j.cgh.2019.01.027. Epub 2019 Jan 29.

17.

miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis.

Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL.

Int J Mol Sci. 2018 Dec 10;19(12). pii: E3966. doi: 10.3390/ijms19123966. Review.

18.

FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage.

Lombardi R, Petta S, Pisano G, Dongiovanni P, Rinaldi L, Adinolfi LE, Acierno C, Valenti L, Boemi R, Spatola F, Craxì A, Fargion S, Fracanzani AL.

Clin Gastroenterol Hepatol. 2020 Feb;18(2):517-519. doi: 10.1016/j.cgh.2018.11.011. Epub 2018 Dec 8.

PMID:
30528844
19.

Genetic and Epigenetic Modifiers of Alcoholic Liver Disease.

Meroni M, Longo M, Rametta R, Dongiovanni P.

Int J Mol Sci. 2018 Dec 3;19(12). pii: E3857. doi: 10.3390/ijms19123857. Review.

20.

Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis.

Zhu C, Kim K, Wang X, Bartolome A, Salomao M, Dongiovanni P, Meroni M, Graham MJ, Yates KP, Diehl AM, Schwabe RF, Tabas I, Valenti L, Lavine JE, Pajvani UB.

Sci Transl Med. 2018 Nov 21;10(468). pii: eaat0344. doi: 10.1126/scitranslmed.aat0344.

21.

FGF23 and Fetuin-A Interaction in the Liver and in the Circulation.

Mattinzoli D, Ikehata M, Tsugawa K, Alfieri CM, Dongiovanni P, Trombetta E, Valenti L, Puliti A, Lazzari L, Messa P.

Int J Biol Sci. 2018 Apr 25;14(6):586-598. doi: 10.7150/ijbs.23256. eCollection 2018.

22.

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease.

Dongiovanni P, Meroni M, Mancina RM, Baselli G, Rametta R, Pelusi S, Männistö V, Fracanzani AL, Badiali S, Miele L, Grimaudo S, Petta S, Bugianesi E, Soardo G, Fargion S, Pihlajamäki J, Romeo S, Valenti L.

Hepatol Commun. 2018 Apr 25;2(6):666-675. doi: 10.1002/hep4.1192. eCollection 2018 Jun.

23.

Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.

Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, Pelusi S, Pingitore P, Badiali S, Maggioni M, Mannisto V, Grimaudo S, Pipitone RM, Pihlajamaki J, Craxi A, Taube M, Carlsson LMS, Fargion S, Romeo S, Kozlitina J, Valenti L.

J Intern Med. 2018 Apr;283(4):356-370. doi: 10.1111/joim.12719. Epub 2017 Dec 27.

24.

Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.

Kim K, Ryu D, Dongiovanni P, Ozcan L, Nayak S, Ueberheide B, Valenti L, Auwerx J, Pajvani UB.

Gastroenterology. 2017 Dec;153(6):1568-1580.e10. doi: 10.1053/j.gastro.2017.08.039. Epub 2017 Aug 30.

25.

Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.

Petta S, Valenti L, Tuttolomondo A, Dongiovanni P, Pipitone RM, Cammà C, Cabibi D, Di Marco V, Fracanzani AL, Badiali S, Nobili V, Fargion S, Grimaudo S, Craxì A.

Hepatology. 2017 Dec;66(6):1885-1893. doi: 10.1002/hep.29395. Epub 2017 Nov 6.

PMID:
28741298
26.

A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease.

Dongiovanni P, Valenti L.

Int J Mol Sci. 2017 Jul 16;18(7). pii: E1534. doi: 10.3390/ijms18071534. Review.

27.

Hepatic iron is the major determinant of serum ferritin in NAFLD patients.

Ryan JD, Armitage AE, Cobbold JF, Banerjee R, Borsani O, Dongiovanni P, Neubauer S, Morovat R, Wang LM, Pasricha SR, Fargion S, Collier J, Barnes E, Drakesmith H, Valenti L, Pavlides M.

Liver Int. 2018 Jan;38(1):164-173. doi: 10.1111/liv.13513. Epub 2017 Jul 29.

PMID:
28679028
28.

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Donati B, Pietrelli A, Pingitore P, Dongiovanni P, Caddeo A, Walker L, Baselli G, Pelusi S, Rosso C, Vanni E, Daly A, Mancina RM, Grieco A, Miele L, Grimaudo S, Craxi A, Petta S, De Luca L, Maier S, Soardo G, Bugianesi E, Colli F, Romagnoli R, Anstee QM, Reeves HL, Fracanzani AL, Fargion S, Romeo S, Valenti L.

Cancer Med. 2017 Aug;6(8):1930-1940. doi: 10.1002/cam4.1078. Epub 2017 Jul 4.

29.

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.

Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S, Romagnoli R, Colli F, Ferri F, Mancina RM, Iruzubieta P, Craxi A, Fracanzani AL, Grieco A, Corradini SG, Aghemo A, Colombo M, Soardo G, Bugianesi E, Reeves H, Anstee QM, Fargion S, Valenti L.

Sci Rep. 2017 Jul 3;7(1):4492. doi: 10.1038/s41598-017-04991-0.

30.

Iron overload induces hypogonadism in male mice via extrahypothalamic mechanisms.

Macchi C, Steffani L, Oleari R, Lettieri A, Valenti L, Dongiovanni P, Romero-Ruiz A, Tena-Sempere M, Cariboni A, Magni P, Ruscica M.

Mol Cell Endocrinol. 2017 Oct 15;454:135-145. doi: 10.1016/j.mce.2017.06.019. Epub 2017 Jun 23.

PMID:
28648620
31.

Mutant PNPLA3 I148M protein as pharmacological target for liver disease.

Valenti L, Dongiovanni P.

Hepatology. 2017 Oct;66(4):1026-1028. doi: 10.1002/hep.29298. Epub 2017 Aug 26. No abstract available.

PMID:
28586091
32.

Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.

Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, Di Marco V, Cammà C, Mensi L, Dongiovanni P, Valenti L, Craxì A, Fargion S.

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.

PMID:
28554682
33.

Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Petta S, Valenti L, Svegliati-Baroni G, Ruscica M, Pipitone RM, Dongiovanni P, Rychlicki C, Ferri N, Cammà C, Fracanzani AL, Pierantonelli I, Di Marco V, Meroni M, Giordano D, Grimaudo S, Maggioni M, Cabibi D, Fargion S, Craxì A.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2660-2669. doi: 10.1210/jc.2017-00056.

PMID:
28472477
34.

Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.

Dongiovanni P, Meroni M, Baselli GA, Bassani GA, Rametta R, Pietrelli A, Maggioni M, Facciotti F, Trunzo V, Badiali S, Fargion S, Gatti S, Valenti L.

Clin Sci (Lond). 2017 Jun 7;131(12):1301-1315. doi: 10.1042/CS20170175. Print 2017 Jun 1.

PMID:
28468951
35.

PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis.

Pingitore P, Dongiovanni P, Motta BM, Meroni M, Lepore SM, Mancina RM, Pelusi S, Russo C, Caddeo A, Rossi G, Montalcini T, Pujia A, Wiklund O, Valenti L, Romeo S.

Hum Mol Genet. 2016 Dec 1;25(23):5212-5222. doi: 10.1093/hmg/ddw341.

36.

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.

Pelusi S, Petta S, Rosso C, Borroni V, Fracanzani AL, Dongiovanni P, Craxi A, Bugianesi E, Fargion S, Valenti L.

PLoS One. 2016 Sep 20;11(9):e0163069. doi: 10.1371/journal.pone.0163069. eCollection 2016.

37.

Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease.

Fracanzani AL, Pisano G, Consonni D, Tiraboschi S, Baragetti A, Bertelli C, Norata GD, Dongiovanni P, Valenti L, Grigore L, Tonella T, Catapano A, Fargion S.

PLoS One. 2016 Sep 14;11(9):e0162473. doi: 10.1371/journal.pone.0162473. eCollection 2016.

38.

GNPAT p.D519G variant and iron metabolism during oral iron tolerance test.

Rametta R, Dongiovanni P, Fargion S, Valenti L.

Hepatology. 2017 Jan;65(1):384-385. doi: 10.1002/hep.28745. Epub 2016 Aug 24. No abstract available.

PMID:
27481658
39.

Liver fat accumulation is associated with circulating PCSK9.

Ruscica M, Ferri N, Macchi C, Meroni M, Lanti C, Ricci C, Maggioni M, Fracanzani AL, Badiali S, Fargion S, Magni P, Valenti L, Dongiovanni P.

Ann Med. 2016 Aug;48(5):384-91. doi: 10.1080/07853890.2016.1188328. Epub 2016 May 25.

PMID:
27222915
40.

Hepcidin resistance in dysmetabolic iron overload.

Rametta R, Dongiovanni P, Pelusi S, Francione P, Iuculano F, Borroni V, Fatta E, Castagna A, Girelli D, Fargion S, Valenti L.

Liver Int. 2016 Oct;36(10):1540-8. doi: 10.1111/liv.13124. Epub 2016 Apr 6.

PMID:
26998752
41.

Nutritional therapy for nonalcoholic fatty liver disease.

Dongiovanni P, Lanti C, Riso P, Valenti L.

J Nutr Biochem. 2016 Mar;29:1-11. doi: 10.1016/j.jnutbio.2015.08.024. Epub 2015 Oct 23. Review.

PMID:
26895659
42.

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.

Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, Borén J, Montalcini T, Pujia A, Wiklund O, Hindy G, Spagnuolo R, Motta BM, Pipitone RM, Craxì A, Fargion S, Nobili V, Käkelä P, Kärjä V, Männistö V, Pihlajamäki J, Reilly DF, Castro-Perez J, Kozlitina J, Valenti L, Romeo S.

Gastroenterology. 2016 May;150(5):1219-1230.e6. doi: 10.1053/j.gastro.2016.01.032. Epub 2016 Feb 2.

43.

The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?

Dongiovanni P, Rametta R, Meroni M, Valenti L.

Expert Rev Gastroenterol Hepatol. 2016;10(2):229-42. doi: 10.1586/17474124.2016.1110018. Epub 2015 Dec 5. Review.

44.

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.

Donati B, Motta BM, Pingitore P, Meroni M, Pietrelli A, Alisi A, Petta S, Xing C, Dongiovanni P, del Menico B, Rametta R, Mancina RM, Badiali S, Fracanzani AL, Craxì A, Fargion S, Nobili V, Romeo S, Valenti L.

Hepatology. 2016 Mar;63(3):787-98. doi: 10.1002/hep.28370. Epub 2016 Jan 14.

PMID:
26605757
45.

MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.

Petta S, Valenti L, Marra F, Grimaudo S, Tripodo C, Bugianesi E, Cammà C, Cappon A, Di Marco V, Di Maira G, Dongiovanni P, Rametta R, Gulino A, Mozzi E, Orlando E, Maggioni M, Pipitone RM, Fargion S, Craxì A.

J Hepatol. 2016 Mar;64(3):682-90. doi: 10.1016/j.jhep.2015.10.016. Epub 2015 Oct 24.

46.

Reply to "Statin treatment for non-alcoholic steatohepatitis".

Dongiovanni P, Pihlajamaki J, Romeo S, Valenti L.

J Hepatol. 2016 Jan;64(1):242-3. doi: 10.1016/j.jhep.2015.09.023. Epub 2015 Oct 8. No abstract available.

PMID:
26456843
47.

Genetics of nonalcoholic fatty liver disease.

Dongiovanni P, Valenti L.

Metabolism. 2016 Aug;65(8):1026-37. doi: 10.1016/j.metabol.2015.08.018. Epub 2015 Sep 1. Review.

PMID:
26409295
48.

Increased circulating adiponectin in males with chronic HCV hepatitis.

Canavesi E, Porzio M, Ruscica M, Rametta R, Macchi C, Pelusi S, Fracanzani AL, Dongiovanni P, Fargion S, Magni P, Valenti L.

Eur J Intern Med. 2015 Oct;26(8):635-9. doi: 10.1016/j.ejim.2015.08.001. Epub 2015 Aug 17.

PMID:
26293833
49.

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis.

Dongiovanni P, Romeo S, Valenti L.

Biomed Res Int. 2015;2015:460190. doi: 10.1155/2015/460190. Epub 2015 Jul 27. Review.

50.

Iron Stores, Hepcidin, and Aortic Stiffness in Individuals with Hypertension.

Valenti L, Maloberti A, Signorini S, Milano M, Cesana F, Cappellini F, Dongiovanni P, Porzio M, Soriano F, Brambilla M, Cesana G, Brambilla P, Giannattasio C, Fargion S.

PLoS One. 2015 Aug 5;10(8):e0134635. doi: 10.1371/journal.pone.0134635. eCollection 2015.

Supplemental Content

Loading ...
Support Center